Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma.

Background: Measuring the activity of hemostatic agents used to treat hemophilia A often requires drug-specific assays. assays show hemophilic clots have abnormal characteristics, including prolonged clotting time and decreased resistance to fibrinolysis. The ability of certain agents to correct these parameters is associated with hemostatic efficacy .